AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6189695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30902911 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus thoracis muscle plane (TTP) block with 20 mL of either 0.3% or 0.5% ropivacaine bilaterally
Number of subjects: 19
Study 30902911 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group, no injections)
Number of subjects: 19
Study 30902911 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus thoracis muscle plane (TTP) block
Number of subjects: 19
Study 30394494 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cold therapy with local sterile frozen ice compress)
Number of subjects: 100
Study 30394494 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional sterile compress)
Number of subjects: 100
Study 26644172 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 341
Study 26644172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 22984171 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg BID
Number of subjects: 38
Study 22984171 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 22113535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical-Combined Pill (berberine 500 mg, policosanol 10 mg, red yeast rice 200 mg, folic acid 0.2 mg, coenzyme Q10 2.0 mg, astaxanthin 0.5 mg)
Number of subjects: 80
Study 22113535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20017910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg of ezetimibe plus 160 mg of fenofibrate)
Number of subjects: 43
Study 20017910 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy (10 mg)
Number of subjects: 43
Study 17005079 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutai Decoction (GTD) - Group A (started from the 2nd day of transferring)
Number of subjects: 247
Study 17005079 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutai Decoction (GTD) - Group B (started from the 14th day after transferring)
Number of subjects: 247
Study 17005079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional GTD treatment)
Number of subjects: 247
Study 15357626 — intervention group
Group type: EXPERIMENTAL
Intervention: Heberon Alfa R (formulation A)
Number of subjects: 14
Study 15357626 — intervention group
Group type: COMPARATOR
Intervention: Viraferon (formulation B)
Number of subjects: 14
Study 15357626 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 14
Study 11132386 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (median total dose of 9.6 mg/kg and 57.9 mg/kg of lumefantrine)
Number of subjects: 200
Study 11132386 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine (12 mg/kg over 3 days and 25 mg/kg)
Number of subjects: 200
Study 9061388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage using Cell Saver
Number of subjects: 37
Study 9061388 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without autotransfusion)
Number of subjects: 37
Study 8400342 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h tube feeding and bag changes (n = 2)
Number of subjects: 20
Study 8400342 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 h tube feeding and bag changes (n = 3)
Number of subjects: 20
Study 8400342 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 h tube feeding and bag changes (n = 6)
Number of subjects: 20
Study 8400342 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h tube feeding and bag changes (n = 6) in the second study
Number of subjects: 20
Study 8400342 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 h tube feeding and bag changes (n = 6) in the second study
Number of subjects: 20
Study 3773022 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 10
Study 28783868 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 0
Study 28783868 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27329582 — intervention group
Group type: EXPERIMENTAL
Intervention: rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation)
Number of subjects: 176
Study 27329582 — intervention group
Group type: COMPARATOR
Intervention: aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation)
Number of subjects: 176
Study 27329582 — intervention group
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Number of subjects: 176
Study 27329582 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 176
Study 24172937 — intervention group
Group type: EXPERIMENTAL
Intervention: DCD‐training group (aerobic exercise intervention for 16 weeks)
Number of subjects: 40
Study 24172937 — intervention group
Group type: COMPARATOR
Intervention: DCD nontraining group (control group)
Number of subjects: 40
Study 21900536 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone nasal septal splints with integral airway
Number of subjects: 51
Study 21900536 — intervention group
Group type: COMPARATOR
Intervention: Merocel nasal packs
Number of subjects: 51
Study 21900536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 20212251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine at 0.12 mg/kg combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (CC regimen)
Number of subjects: 423
Study 20212251 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine at 25 mg/m2 combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (FC regimen)
Number of subjects: 423
Study 18492235 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training programme (8-week duration, started after usual care)
Number of subjects: 0
Study 18492235 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18249370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved seminal plasma
Number of subjects: 168
Study 18249370 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (placebo)
Number of subjects: 168
Study 15452834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel (two dose levels)
Number of subjects: 399
Study 15452834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel
Number of subjects: 399
Study 12269651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 2% eyedrops
Number of subjects: 24
Study 12269651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 24
Study 9470082 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 67
Study 9470082 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 67
Study 7943303 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle biopsy from the vastus lateralis muscle (study B)
Number of subjects: 8
Study 7943303 — intervention group
Group type: COMPARATOR
Intervention: Control study (study C)
Number of subjects: 8
Study 3794876 — intervention group
Group type: EXPERIMENTAL
Intervention: Three weekly (tiw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Number of subjects: 0
Study 3794876 — intervention group
Group type: COMPARATOR
Intervention: Two weekly (biw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Number of subjects: 0
Study 11728078 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (n 12, 2 x 100 mg)
Number of subjects: 39
Study 11728078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (n 14, 2 x 300 mg)
Number of subjects: 39
Study 11728078 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n 13)
Number of subjects: 39
Study 31345626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Number of subjects: 660
Study 31345626 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (48.6 Gy in 1.8 Gy fractions)
Number of subjects: 660
Study 31345626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 660
Study 31345626 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 660
Study 29952013 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting anti-virals
Number of subjects: 182
Study 29952013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryoglobulinaemia)
Number of subjects: 182
Study 27016545 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated family planning and immunization services
Number of subjects: 1654
Study 27016545 — intervention group
Group type: COMPARATOR
Intervention: Standard immunization services only
Number of subjects: 1654
Study 25026672 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Pest Management (IPM)
Number of subjects: 0
Study 25026672 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Application of Pesticide (WAP)
Number of subjects: 0
Study 25026672 — intervention group
Group type: COMPARATOR
Intervention: Nonpesticide Application (Control)
Number of subjects: 0
Study 21493664 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 18
Study 20093894 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement (1,200 mg eicosapentaenoic acid and 800 mg docosahexaenoic acid)
Number of subjects: 852
Study 20093894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 852
Study 17484697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement interventions with children
Number of subjects: 13
Study 17484697 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-sensitive interventions and specific selection criteria
Number of subjects: 13
Study 16127078 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg administered over 1 h every 8 h
Number of subjects: 0
Study 16127078 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusions of doripenem
Number of subjects: 0
Study 12173383 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (20 Gy/5 days)
Number of subjects: 102
Study 12173383 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control group)
Number of subjects: 102
Study 10100044 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing with water
Number of subjects: 3
Study 10100044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 3
Study 10100044 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum
Number of subjects: 3
Study 10100044 — intervention group
Group type: COMPARATOR
Intervention: No toothbrushing
Number of subjects: 3
Study 7608317 — intervention group
Group type: EXPERIMENTAL
Intervention: Roferon-A reconstituted with 10 mg of HSA
Number of subjects: 24
Study 7608317 — intervention group
Group type: COMPARATOR
Intervention: Roferon-A reconstituted with HSA-free diluent
Number of subjects: 24
Study 1978736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (FD) at doses from 0.05 to 0.50 micrograms/kg/min
Number of subjects: 10
Study 1978736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (FD) combined with Metoclopramide (MCP)
Number of subjects: 10
Study 1978736 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MCP)
Number of subjects: 10
Study 1978736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 328540 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and hydrochlorothiazide combination therapy
Number of subjects: 32
Study 328540 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 32
Study 30723739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training of the pelvic floor muscles (PFM) and the transversus abdominis (TrA) muscle (Group A)
Number of subjects: 137
Study 30723739 — intervention group
Group type: COMPARATOR
Intervention: Isolated pelvic floor muscles exercises (Group B)
Number of subjects: 137
Study 29243273 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for nonsleepy OSA patients (n = 122)
Number of subjects: 277
Study 29243273 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for sleepy OSA patients (n = 155)
Number of subjects: 277
Study 25656133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% polar sunflower seed oil
Number of subjects: 3
Study 25656133 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% polar glyceryl trioleate
Number of subjects: 3
Study 25656133 — intervention group
Group type: COMPARATOR
Intervention: 1% non-polar mineral oil
Number of subjects: 3
Study 25656133 — intervention group
Group type: COMPARATOR
Intervention: 10% non-polar dodecane
Number of subjects: 3
Study 24531742 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET)
Number of subjects: 26
Study 24531742 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 26
Study 24531742 — intervention group
Group type: COMPARATOR
Intervention: Both RET and AET
Number of subjects: 26
Study 23017308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 51
Study 19716598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg once daily)
Number of subjects: 2739
Study 19716598 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2739
Study 17475734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 1439
Study 17475734 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch strategy
Number of subjects: 1439
Study 17475734 — intervention group
Group type: COMPARATOR
Intervention: Augmentation strategy
Number of subjects: 1439
Study 15186737 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b, cyclophosphamide, and prednisone as maintenance therapy
Number of subjects: 169
Study 15186737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maintenance therapy)
Number of subjects: 169
Study 15143717 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangtang Bushen Recipe (JBR) in addition to dietotherapy and kinetotherapy
Number of subjects: 51
Study 15143717 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietotherapy and kinetotherapy only)
Number of subjects: 51
Study 15143717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 15143717 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM group (JBR)
Number of subjects: 51
Study 15143717 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM group
Number of subjects: 51
Study 11297816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 60 min)
Number of subjects: 8
Study 11297816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9043726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.03 mg.kg‐1 sl), morphine (0.15 mg.kg‐1 im), and perphenazine (0.05 mg.kg‐1 im)
Number of subjects: 68
Study 9043726 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (0.03 mg.kg‐1 sl) and saline (1.5 ml im)
Number of subjects: 68
Study 7709624 — intervention group
Group type: EXPERIMENTAL
Intervention: Single procedure of manual therapy
Number of subjects: 46
Study 3108586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus pelvic radiation
Number of subjects: 45
Study 3108586 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pelvic radiation
Number of subjects: 45
Study 30037355 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day preoperative decolonization bundle (nasal mupirocin, chlorhexidine gluconate bathing, and chlorhexidine mouthwash)
Number of subjects: 110
Study 30037355 — intervention group
Group type: COMPARATOR
Intervention: 2 preoperative showers with antiseptic soap (control)
Number of subjects: 110
Study 28207529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine without loading dose (PRDo)
Number of subjects: 70
Study 28207529 — intervention group
Group type: COMPARATOR
Intervention: Propofol/remifentanil/Ringer solution (PRR)
Number of subjects: 70
Study 28207529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with loading dose (PRDw)
Number of subjects: 70
Study 25731985 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimpanzees (Pan troglodytes)
Number of subjects: 0
Study 25731985 — intervention group
Group type: COMPARATOR
Intervention: Baboons (Papio papio)
Number of subjects: 0
Study 23192756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardionet mobile cardiac outpatient telemetry monitor for 21 days
Number of subjects: 40
Study 23192756 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up alone
Number of subjects: 40
Study 21509720 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin added to cardioplegia
Number of subjects: 60
Study 21509720 — intervention group
Group type: COMPARATOR
Intervention: Control (no nitroglycerin)
Number of subjects: 60
Study 18280850 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system
Number of subjects: 306
Study 18280850 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 306
Study 17315426 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia with pethidine (25 mg of five mg/ml solution, lockout of 10 minutes, maximum dose of 150 mg/four hours)
Number of subjects: 34
Study 17315426 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered epidural pethidine (bolus of 50 mg, maximum dose of 50 mg/two hours)
Number of subjects: 34
Study 14626183 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus injection (AI) combined with chemotherapy
Number of subjects: 60
Study 14626183 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 60
Study 10930183 — intervention group
Group type: EXPERIMENTAL
Intervention: P592S mutation
Number of subjects: 803
Study 10930183 — intervention group
Group type: COMPARATOR
Intervention: T594M mutation
Number of subjects: 803
Study 8962554 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis plus simvastatin
Number of subjects: 42
Study 8962554 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (simvastatin)
Number of subjects: 42
Study 14621717 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA/AZA
Number of subjects: 44
Study 14621717 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 44
Study 3842611 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 77
Study 3842611 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamiro 370
Number of subjects: 77
Study 3842611 — intervention group
Group type: COMPARATOR
Intervention: Urovison
Number of subjects: 77
Study 3842611 — intervention group
Group type: COMPARATOR
Intervention: Urografin
Number of subjects: 77
Study 3842611 — intervention group
Group type: COMPARATOR
Intervention: All contrast agents
Number of subjects: 77
Study 30815731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + QMix + EndoActivator (G4)
Number of subjects: 104
Study 30815731 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl + EndoActivator (G2)
Number of subjects: 104
Study 30815731 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl + QMix + conventional endodontic syringe (G3)
Number of subjects: 104
Study 30815731 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl + conventional endodontic syringe (G1)
Number of subjects: 104
Study 27791254 — intervention group
Group type: EXPERIMENTAL
Intervention: AGV with adjunctive triamcinolone (TA group)
Number of subjects: 90
Study 27791254 — intervention group
Group type: COMPARATOR
Intervention: Conventional AGV (non-TA group)
Number of subjects: 90
Study 25684073 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit instruction to consider non-health-related utility in TTO exercises
Number of subjects: 104
Study 25684073 — intervention group
Group type: COMPARATOR
Intervention: No explicit instruction for the consideration of consumption and leisure effects in TTO exercise
Number of subjects: 104
Study 24686255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 0.03 mg/kg
Number of subjects: 217
Study 24686255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 0.1 mg/kg
Number of subjects: 217
Study 24686255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 0.3 mg/kg
Number of subjects: 217
Study 24686255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 21986695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 22
Study 21986695 — intervention group
Group type: COMPARATOR
Intervention: Control (quiet sitting)
Number of subjects: 22
Study 19443679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 90
Study 19443679 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 90
Study 19443679 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg and Ezetimibe 10 mg
Number of subjects: 90
Study 17877648 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera; EXU)
Number of subjects: 922
Study 17877648 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 922
Study 17877648 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea (glibenclamide)
Number of subjects: 922
Study 15077226 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (740 mg/m2 for 2 doses preceding BCNU)
Number of subjects: 79
Study 15077226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 12453890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mU · kg1 · min‐1 insulin infusion
Number of subjects: 8
Study 12453890 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 10209349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 5 mg
Number of subjects: 544
Study 10209349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 544
Study 10209349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 544
Study 10209349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544